IVA Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Inventiva SA has a consensus price target of $15.33, signalling upside risk potential of 245.35%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 109.38%. Given that Inventiva SA has higher upside potential than DBV Technologies SA, analysts believe Inventiva SA is more attractive than DBV Technologies SA.

Inventiva SA has a beta of 0.746, which suggesting that the stock is 25.433% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Inventiva SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Inventiva SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 25.85x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

EDAP TMS SA has a net margin of -- compared to Inventiva SA's net margin of -36.13%. Inventiva SA's return on equity of -- beat EDAP TMS SA's return on equity of -56.97%.

Inventiva SA has a consensus price target of $15.33, signalling upside risk potential of 245.35%. On the other hand EDAP TMS SA has an analysts' consensus of $5.83 which suggests that it could grow by 96.4%. Given that Inventiva SA has higher upside potential than EDAP TMS SA, analysts believe Inventiva SA is more attractive than EDAP TMS SA.

Inventiva SA has a beta of 0.746, which suggesting that the stock is 25.433% less volatile than S&P 500. In comparison EDAP TMS SA has a beta of -0.152, suggesting its less volatile than the S&P 500 by 115.246%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EDAP TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. EDAP TMS SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than EDAP TMS SA quarterly revenues of $16.2M. Inventiva SA's net income of -- is lower than EDAP TMS SA's net income of -$5.9M. Notably, Inventiva SA's price-to-earnings ratio is -- while EDAP TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 25.85x versus 1.58x for EDAP TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Inventiva SA has a consensus price target of $15.33, signalling upside risk potential of 245.35%. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 203.18%. Given that Inventiva SA has higher upside potential than Innate Pharma SA, analysts believe Inventiva SA is more attractive than Innate Pharma SA.

Inventiva SA has a beta of 0.746, which suggesting that the stock is 25.433% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 25.85x versus 21.95x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Nanobiotix SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Nanobiotix SA's return on equity of --.

Inventiva SA has a consensus price target of $15.33, signalling upside risk potential of 245.35%. On the other hand Nanobiotix SA has an analysts' consensus of $14.75 which suggests that it could fall by -30.73%. Given that Inventiva SA has higher upside potential than Nanobiotix SA, analysts believe Inventiva SA is more attractive than Nanobiotix SA.

Inventiva SA has a beta of 0.746, which suggesting that the stock is 25.433% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 25.85x versus 31.60x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.